A Multicenter, International, Phase 3, Double-Blind, Pla

Project: Research project

Description

A Multicenter, International, Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 mg or 80 mg
StatusActive
Effective start/end date9/10/149/9/21

Funding

  • PFIZER, INC.

Fingerprint

Placebos
Safety
tafamidis